DanioLabs and Senexis Announce Collaboration on Ageing Related Diseases

DanioLabs, the neurology and ophthalmology drug reprofiling company, today announced the signing of a strategic collaboration with Senexis, a private drug development company, focused on discovering new treatments for ageing-related diseases.

CAMBRIDGE, UK | Jan 16, 2006 |
DanioLabs, the neurology and ophthalmology drug reprofiling company, today announced the signing of a strategic collaboration with Senexis, a private drug development company, focused on discovering new treatments for ageing-related diseases.

DanioLabs has pioneered development of medium/high throughput, high content in vivo assays utilizing its cutting edge zebrafish technology. Known drugs and pharmacological probes are screened with a view to minimizing the risk of drug development. It has two programmes with positive clinical data and a strong preclinical pipeline. DanioLabs has a major neurodegeneration programme covering Parkinson’s, Alzheimer’s and Huntington’s diseases, as well as multiple sclerosis. It is currently screening for small molecules which rescue the underlying pathologies of these disease states as well as ameliorating the cognitive impairment associated with various forms of dementias.

Senexis is developing new chemical entities as inhibitors of amyloid-related toxicity and inflammation in Alzheimer’s disease. It is expected that the combination of the two complementary approaches will offer a significant opportunity to develop novel molecules with potential of becoming disease-modifying therapies for Alzheimer’s disease.

Paul Goldsmith, CSO of DanioLabs said: “We are excited about this collaboration because it brings Senexis’ chemistry together with our biology. It marks an important transition for us as we move from assay development and validation to the process of identifying and progressing therapeutic candidate drugs”.

"We are delighted to be collaborating with DanioLabs," commented Dr Mark Treherne, Senexis’ Chief Executive. “We look forward to a productive and fruitful collaboration”.

For further information please contact:
DanioLabs
Dr Tony Sedgwick, CEO Tel: +44(0)1223 706460
Dr Paul Goldsmith, CSO Tel: +44(0)1223 706460

Senexis
Dr Mark Treherne Tel: +44 (0)1223 496160

Northbank Communications Tel: +44(0)203 008 7550
Gemma Bradley / Katja Stout / Justine Lamond



Note to Editors: About DanioLabs
DanioLabs is a biotechnology company focused on developing products in the fields of neurology and ophthalmology. The Company has a reprofiling strategy; identifying and enhancing known drug compounds for new, innovative therapeutic applications, with the aim of out-licensing products for further development and commercialisation. DanioLabs has a portfolio of clinical and preclinical programmes, with its drug discovery programmes supported by collaborations with the CIMR (Cambridge Institute for Medical Research) and Cambridge Centre for Brain Repair, at the University of Cambridge. Its Alzheimer models display amyloid-related pathology.

Note to Editors: About Senexis
Senexis is a drug development company, dedicated to the discovery of effective treatments and diagnostics for major ageing-related diseases, such as Alzheimer's dementia, type II diabetes and dialysis related amyloidosis. It is now widely believed that the misfolding and aggregation of amyloid-like proteins underlies the pathologies of these different diseases. Senexis has discovered potent and selective compounds that protect cells and tissues from the toxic forms of amyloid. Senexis is funded by BTG plc and the Wellcome Trust. Further information on Senexis can be found at www.senexis.com

SOURCE: DanioLabs

La Merie Biologics

FREE Weekly News Bulletin

Sign Up

2020 Sales ofAntibodies & Proteins

New Product Alert

For La Merie Publishing

Sign Up

Top